
Novartis lays out blockbuster launches for 2018-2020, with surprising inclusion of Kymriah
As Novartis shakes off its Alcon eye business and the loss of two high-profile executives, chief Vas Narasimhan has outlined the Swiss drugmaker’s roster of 14 blockbuster launches, a bulk of which are expected to win approval between this year and 2020. The drugs included in the list are largely familiar, but the inclusion of the company’s pioneering CAR-T therapy Kymriah, whose adoption has been wobbly due to manufacturing woes, will raise some eyebrows.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.